Trial Profile
An Open Label Dose Escalation/Expansion Study of Tremelimumab Alone or Combined With Olaparib for Recurrent or Persistent EOC (Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Carcinoma)
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 31 Mar 2022
Price :
$35
*
At a glance
- Drugs Olaparib (Primary) ; Tremelimumab (Primary)
- Indications Carcinoma; Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Adverse reactions; Therapeutic Use
- 29 Jun 2020 Status changed from active, no longer recruiting to discontinued.
- 31 May 2020 Results (n=24) presented at the 56th Annual Meeting of the American Society of Clinical Oncology.
- 06 Jan 2020 Planned primary completion date changed from 1 Dec 2019 to 1 Dec 2020.